6BL4
Crystal Complex of Cyclooxygenase-2 with indomethacin-ethylenediamine-dansyl conjugate
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | APS BEAMLINE 24-ID-C |
Synchrotron site | APS |
Beamline | 24-ID-C |
Temperature [K] | 100 |
Detector technology | PIXEL |
Collection date | 2014-06-24 |
Detector | DECTRIS PILATUS 6M-F |
Wavelength(s) | 0.97918 |
Spacegroup name | C 1 2 1 |
Unit cell lengths | 214.795, 120.414, 134.417 |
Unit cell angles | 90.00, 123.60, 90.00 |
Refinement procedure
Resolution | 111.959 - 2.220 |
R-factor | 0.1895 |
Rwork | 0.189 |
R-free | 0.21950 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 3nt1 |
RMSD bond length | 0.012 |
RMSD bond angle | 1.013 |
Data reduction software | XDS |
Data scaling software | Aimless (0.1.27) |
Phasing software | PHASER |
Refinement software | PHENIX (1.12_2829) |
Data quality characteristics
Overall | Inner shell | Outer shell | |
Low resolution limit [Å] | 111.960 | 111.960 | 2.340 |
High resolution limit [Å] | 2.220 | 7.020 | 2.220 |
Rmerge | 0.110 | 0.027 | 0.677 |
Rmeas | 0.144 | 0.036 | 0.886 |
Rpim | 0.093 | 0.024 | 0.566 |
Total number of observations | 325121 | ||
Number of reflections | 138444 | 4542 | 20005 |
<I/σ(I)> | 9.3 | ||
Completeness [%] | 98.7 | 99.3 | 97.9 |
Redundancy | 2.3 | 2.3 | 2.4 |
CC(1/2) | 0.985 | 0.997 | 0.555 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, HANGING DROP | 6.7 | 291 | mCOX-2 protein reconstituted with a 2-fold molar excess of heme in phosphtate buffer, pH 6.7, 100 mM NaCl, 1.2% (w/v) -OG, and 0.1% NaN3, and 10-fold molar excess of inhibitors from 25 mM DMSO stocks were added to protein samples. Mixing 3 uL of the protein-inhibitor complex with 3 uL crystallization solution containing 50 mM EPPS, pH 8.0, 120 mM MgCl2, 22-26% PEG MME-550 against reservoir solutions comprised of 50 mM EPPS pH 8.0, 120 mM MgCl2, 22-26% PEG MME-550, VAPOR DIFFUSION, HANGING DROP, temperature 291K |